Intended for healthcare professionals

  1. Research
  2. Prevalence of...
  3. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey
Papers

Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey

BMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7253.78 (Published 08 July 2000) Cite this as: BMJ 2000;321:78
  1. Shane Allwright (sllwrght{at}tcd.ie), senior lecturer in epidemiologya,
  2. Fiona Bradley, lecturer in general practicea,
  3. Jean Long, lecturer in international health and developmenta,
  4. Joseph Barry, senior lecturer in public healtha,
  5. Lelia Thornton, specialist in public health medicineb,
  6. John V Parry, deputy directorc
  1. a Department of Community Health and General Practice, Trinity College, Dublin 2, Republic of Ireland,
  2. b Department of Public Health, Eastern Regional Health Authority, Dr Steevens' Hospital, Dublin 8, Republic of Ireland,
  3. c Hepatitis and Retrovirus Laboratory, PHLS Central Public Health Laboratory, London NW9 5HT
  1. Correspondence to: S Allwright
  • Accepted 30 March 2000

Abstract

Objectives: To determine the prevalence of antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in the prison population of the Republic of Ireland and to examine risk factors for infection.

Design: Cross sectional, anonymous, unlinked survey, with self completed risk factor questionnaire and provision of oral fluid specimen for antibody testing.

Setting: Nine of the 15 prisons in the Republic of Ireland.

Participants: 1366 prisoners, of whom 1205 (57 women) participated. In the smaller prisons all prisoners were surveyed, while in the three largest prisons one half of the population was randomly sampled. Three small prisons believed not to have a problem with injecting drug use were excluded.

Main outcome measures: Prevalence of antibodies to hepatitis B core antigen, antibodies to hepatitis C virus, and antibodies to HIV. Self reported risk factor status.

Results: Prevalence of antibodies to hepatitis B core antigen was 104/1193 (8.7%; 95% confidence interval 7.2% to 10.5%), to hepatitis C virus, 442/1193 (37%; 34.3% to 39.9%), and to HIV, 24/1193 (2%; 1.3% to 3%). The most important predictor of being positive for hepatitis B and hepatitis C was a history of injecting drug use. Thirty four women (60%) and 474 men (42%) reported ever injecting drugs. A fifth (104) of 501 injecting drug users reported first injecting in prison, and 347 (71%) users reported sharing needles in prison.

Conclusions: Infection with hepatitis C secondary to use of injected drugs is endemic in Irish prisons. Better access to harm reduction strategies is needed in this environment.

Footnotes

  • Funding Department of Justice, Equality and Law Reform, Republic of Ireland.

  • Competing interests FB has contributed to policy development on prison health for the Labour party and, until recently, was a part time prison medical officer. JB is a member of the National Drugs Strategy Team. Though the study was funded by Department of Justice, Equality and Law Reform, Republic of Ireland, the research contract guaranteed freedom to publish results in a peer reviewed journal.

  • Embedded Image Extra tables of results can be found on the BMJ's website

View Full Text
Back to top